高雄義大醫院 外科部 泌尿科
Effect of Denosumab on osteoporosis in kidney transplant recipients
Sih-Han Chen1、Hua-Pin Wang1、Chun-Hsien Wu1
Divisions of Urology, Department of Surgery, E-Da Hospital, Kaohsiung, Taiwan
Purpose: We investigate the efficacy of denosumab (60 mg every 6 months for 12 months) to treat post kidney transplantation osteoporosis.
Materials and Methods: A total of 19 post kidney transplant patients who had osteoporosis in accordance with World Health Organization criteria for the definition (T score ≤ −2.5 SD) were included in the study. Post kidney transplant patients undergoing treatment between 2015 and 2018 were enrolled and followed up for one year. They were divided into two groups: denosumab (DNS) group and control group. Lumbar 1-4, total hip and femoral neck BMD levels were measured by a dual-energy X-ray absorptiometry (DXA) at baseline and 12 months. All patients had calcium and vitamin D supplementation.
Results: Nine patients were in the DNS group, and ten patients were in the control group. Total lumbar spine BMD increased in DNS treatment-arm (0.75±0.04 g/cm2 to 0.80±0.05 g/cm2; p=0.017). Total hip BMD increased in DNS treatment-arm (0.62±0.07 g/cm2 to 0.67±0.06 g/cm2; p=0.011). DNS-administration resulted in higher increase from baseline in total lumbar BMD compared to control group, however, did not reach statistical significance (DNS vs control: 6.16%±5.68 vs 2.1%±5.28, p=0.086).
Conclusions: Our 1- year follow up data indicated that denosumab increased BMD in kidney transplant patients with osteoporosis.